

Title: Revolutionizing Non-Small Cell Lung Cancer Treatment: The Dawn of Precision Oncology Through Immunotherapy and Targeted Therapies

Dr. Joseph Siu-Kie AU, Hong Kong Adventist Hospital Oncology Centre

Abstract:

The landscape of non-small cell lung cancer (NSCLC) treatment is undergoing a transformative shift, heralding the dawn of precision oncology. This evolution is driven by the integration of immunotherapy and targeted therapies, which are setting new benchmarks for patient outcomes. The forthcoming talk aims to dissect the current state and future prospects of treating NSCLC, emphasizing the role of these advanced therapeutic modalities.

NSCLC, accounting for approximately 85% of lung cancer cases, has historically presented significant treatment challenges due to its heterogeneity and late diagnosis. However, the advent of precision medicine, characterized by the identification of specific genetic mutations and the immune landscape of tumors, has paved the way for more personalized treatment approaches. Immunotherapy, leveraging the patient's immune system to combat cancer, and targeted therapies, aimed at specific molecular alterations in cancer cells, have emerged as game-changers in this context.

Our discussion will delve into recent clinical trial results, highlighting how they have shifted the paradigm from a one-size-fits-all approach to a more tailored strategy. We will explore the critical role of biomarker testing in identifying eligible patients and the impact of these therapies on survival rates, quality of life, and disease progression. Furthermore, the presentation will address the challenges of resistance to these therapies and the ongoing research aimed at overcoming these hurdles.

By showcasing the latest advancements and future directions in the field of precision oncology for NSCLC, this presentation aims to inspire continued innovation and collaboration among researchers, clinicians, and stakeholders in the quest to conquer lung cancer.

In conclusion, the era of precision oncology for NSCLC, marked by the integration of immunotherapy and targeted therapies, represents a significant leap forward in cancer care. This session will provide a comprehensive overview of how these developments are reshaping the treatment landscape, offering new hope to patients and charting the course for future breakthroughs.